Overview

Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety and tolerability of oral administration of PTL201 for relief of spasticity-related symptoms in 70 MS patients and to evaluate the efficacy of oral administration of PTL201 in relief of spasticity-related symptoms in MS patients. The pharmacokinetics of PTL201 in comparison to buccally administered Sativex will be evaluated in sub-study prior to the efficacy study.

Phase:

Phase 2

Details

Lead Sponsor:

PhytoTech Therapeutics, Ltd.

Treatments:

Dronabinol